Team

Picture of Michael Moritz

Michael Moritz

Managing Partner

Telephone: +49 30 809 33 47-13

LinkedIn

@

Picture of Mark Miller

Mark Miller

Managing Partner

Telephone: +49 40 300 836-11

LinkedInXING

@

Picture of Caspar Graf Stauffenberg

Caspar Graf Stauffenberg

Managing Partner

Telephone: +49 89 255 49 53-11

LinkedIn

@

Picture of Daniel Garlipp

Daniel Garlipp

Managing Partner

Telephone: +49 40 300 836-19

LinkedIn

@

Picture of Daniel Dies

Daniel Dies

Partner

Telephone: +49 40 300 836-16

LinkedIn

@

Picture of Manfred Drax

Manfred Drax

Partner

Telephone: +49 89 255 49 53-15

LinkedIn

@

Picture of Anders Elgemyr

Anders Elgemyr

Managing Partner

Telephone: +46 70 496 18 15

LinkedIn

@

Picture of Arnold Holle

Arnold Holle

Managing Partner

Telephone: +44 207 395 27 90

LinkedIn

@

Picture of Esplanade 41

Esplanade 41

20354 Hamburg

Telephone: +49 40 300 83 60

LinkedIn

@

Picture of Mark Miller

Mark Miller

Managing Partner

Telephone: +49 40 300 836-11

LinkedInXING

@

Picture of Daniel Garlipp

Daniel Garlipp

Managing Partner

Telephone: +49 40 300 836-19

LinkedIn

@

Picture of Daniel Dies

Daniel Dies

Partner

Telephone: +49 40 300 836-16

LinkedIn

@

Picture of Anna-Lena Kickbusch

Anna-Lena Kickbusch

Office Management & Accounting

Telephone: +49 40 300 836 10

LinkedIn

@

Picture of Elaine Kelly

Elaine Kelly

PR, Marketing & Business Development Manager

Telephone: +49 40 300 836 18

LinkedIn

@

Picture of Mischa Krause

Mischa Krause

Vice President

Telephone: +49 40 300 836-24

LinkedIn

@

Picture of Kurfürstendamm 188

Kurfürstendamm 188

10707 Berlin

Telephone: +49 30 809 334 70

LinkedIn

@

Picture of Michael Moritz

Michael Moritz

Managing Partner

Telephone: +49 30 809 33 47-13

LinkedIn

@

Picture of Eva Macha

Eva Macha

Office Management

Telephone: +49 30 809 33 47-10

LinkedIn

@

Picture of Jessica Algner

Jessica Algner

Office Management

Telephone: +49 30 809 33 47-12

LinkedIn

@

Picture of Nils Zettelmeyer

Nils Zettelmeyer

Vice President

Telephone: +49 30 809 33 47-25

LinkedIn

@

Picture of Von-der-Tann-Straße 7

Von-der-Tann-Straße 7

80539 München

Telephone: +49 89 255 495 30

LinkedIn

@

Picture of Caspar Graf Stauffenberg

Caspar Graf Stauffenberg

Managing Partner

Telephone: +49 89 255 49 53-11

LinkedIn

@

Picture of Manfred Drax

Manfred Drax

Partner

Telephone: +49 89 255 49 53-15

LinkedIn

@

Picture of Naomi Käfer

Naomi Käfer

Office Management & HR

Telephone: +49 89 255 49 53-10

LinkedIn

@

Picture of Nico Schmidt-Weidemann

Nico Schmidt-Weidemann

Director

Telephone: +49 89 255 49 53-17

@

Picture of Sebastian Fischer

Sebastian Fischer

Vice President

Telephone: +49 89 255 49 53-12

LinkedIn

@

Picture of Birger Jarlsgatan 13

Birger Jarlsgatan 13

111 45 Stockholm

Telephone: +46 8 684 439 00

LinkedIn

@

Picture of Anders Elgemyr

Anders Elgemyr

Managing Partner

Telephone: +46 70 496 18 15

LinkedIn

@

Picture of Erik Lundberg

Erik Lundberg

Director

Telephone: +46 73 850 35 59

LinkedIn

@

Picture of Caroline Berglund

Caroline Berglund

Strategic Business Manager

Telephone: +46 73 382 10 82

LinkedIn

@

Picture of Jonatan Eriksson

Jonatan Eriksson

Vice President

Telephone: +46 72 206 10 24

LinkedIn

@

Picture of Magnus Haegermark

Magnus Haegermark

Vice President

Telephone: +46 73 759 76 54

LinkedIn

@

Picture of Viktor Borg

Viktor Borg

Associate

Telephone: +46 72 742 91 40

LinkedIn

@

Picture of Niki Ngiam

Niki Ngiam

Associate

Telephone: +46 70 579 98 99

LinkedIn

@

Picture of David Pode

David Pode

Senior Analyst

Telephone: +46 70 540 99 55

LinkedIn

@

Picture of Carl Nordström

Carl Nordström

Analyst

Telephone: +46 70 949 94 00

LinkedIn

@

Picture of Markus Augustsson

Markus Augustsson

Head of Equity Research

Telephone: +46 76 235 03 20

LinkedIn

@

Picture of Bertil Nilsson

Bertil Nilsson

Senior Equity Analyst

Telephone: +46 70 434 90 03

LinkedIn

@

Picture of Niklas Elmhammer

Niklas Elmhammer

Senior Equity Analyst

Telephone: +46 70 898 39 59

LinkedIn

@

Picture of Mats Hyttinge

Mats Hyttinge

Senior Equity Analyst

Telephone: +46 73 338 50 67

LinkedIn

@

Picture of Bengt Furberg

Bengt Furberg

Medical expert

@

Picture of Lars Johansen

Lars Johansen

IT&Telecom Expert

@

Picture of 14 Buckingham Street

14 Buckingham Street

London WC2N 6DF

Telephone: +44 20 739 527 90

LinkedIn

@

Picture of Arnold Holle

Arnold Holle

Managing Partner

Telephone: +44 207 395 27 90

LinkedIn

@

Picture of Philipp Claus

Philipp Claus

Associate

Telephone: +44 20 7395 2790

LinkedIn

@

shutterstock 246073315

CatCap advises c-LEcta on financing round by Capricorn Venture Partners and bm|t

29 Aug 2018

c-LEcta, a world-leading biotechnology company focused on enzyme engineering and applications in regulated markets like food and pharma, has closed a financing round with Capricorn Venture Partners and the German investment company bm|t. The capital increase, advised by CatCap, provides the company with growth capital as well as valuable access to an international network.

c-LEcta already has a diversified shareholder structure. In addition to the founder, Dr. Marc Struhalla, private industrial investors and German institutionals, the company has now expanded its circle of shareholders by attracting international investors. c-LEcta has received growth capital from two new shareholders. Lead investor, Capricorn Venture Partners, is an independent, internationally oriented investment company, based in Leuven, Belgium. Capricorn invests in innovative, technology driven companies and has a multidisciplinary team of experienced investment professionals. Capricorn invested through two funds, namely the Capricorn Sustainable Chemistry Fund NV and Quest for Growth NV.

The German investment company bm|t invests in high-growth technology companies led by entrepreneurial teams. bm|t invested via the MFT Mittelstands-Fonds Thüringen GmbH [&] Co. KG. These new funds are planned to be particularly invested in the approval, launch and scale-up of 

products from the project pipeline, further development of the pipeline as well as the expansion of international sales.
c-LEcta is a fully integrated world-leading biotechnology company with focus on enzyme engineering and application in regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs around 60 people. c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than 10 successfully commercialized high-value industrial biotech products.

Mr. Ludwig Goris, Investment Manager of Capricorn, commented on the investment in c-LEcta: “We see that global mega trends and challenges in human nutrition are paving the way for industrial biotech companies like c-LEcta. Since its foundation, c-LEcta has built up a remarkable track record of technology and product development and has been able to validate that through a growing customer base of leading pharma, chemical and food ingredient companies. In addition, we were impressed by the highly qualified team in Leipzig. Founder and CEO Dr. Marc Struhalla and his motivated team have created a great company that has arrived at an attractive inflection point where the current product pipeline forms the foundation for an accelerated growth curve. We are proud to lead this growth capital round and contribute to the success of c-LEcta.”

Kevin Reeder, CEO of bm|t added, “bm|t, which has a substantial life sciences portfolio, is very optimistic about its investment in c-LEcta. The company´s strong team, track record of successful development, and a highly compelling product pipeline were extremely impressive. We feel c-LEcta is well-positioned to transition to a high-value biotechnology product company.” The two new investors expand the group of shareholders, which previously included the following investors: SHS Gesellschaft für Beteiligungsmanagement mbH, High-Tech Gründerfonds Management GmbH, KfW Bankengruppe, Dr. Marc Struhalla, Warning Beteiligungs GmbH, Dr. Bader Beteiligungs GmbH, and Arthur Steinmetz Beteiligungs GmbH.

CEO Dr. Marc Struhalla commented on c-LEcta’s core technology and the capital increase: “The performance requirements for enzymes to be applied in industrial processes are in most cases very specific and vary from naturally occurring variations. Enzymes therefore need to be adapted to industrial conditions via enzyme engineering, and c-LEcta owns one of the most efficient technology platforms in this area. For enzyme optimization as well as for the development of artificial enzyme activities, we use patent-protected strategies that are inspired by nature. The industrial application of these technologies holds great market potential. The financial strength and valuable international network that we have gained through this financing round now offers us the opportunity to develop the full potential of our technology and people. With Capricorn Venture Partners and bm|t, we get two active investors on board that can contribute substantially to our international growth ambitions. Also, I am all the more pleased that our new CFO Thomas Pfaadt will support us in this endeavor. Our goal is that in the future c-LEcta´s technology will be employed in many things we encounter in everyday life.”

 

Contact:

Caspar Stauffenberg

Sebastian Fischer

Gerrit Zwarg